Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.58 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.58 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 5/20 | 0.50 |
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.43 |
| ▸ | RORA | P35398 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850765 | 1.00 | KDR (0.58) | KDRKITRAF1LCKRET | |
| SCHEMBL4843470 | 0.92 | KDR (0.56) | KDRKITRAF1LCKRET | |
| SCHEMBL4843463 | 0.92 | KDR (0.56) | KDRKITRAF1LCKRET | |
| SCHEMBL4845253 | 0.91 | KDR (0.54) | KDRKITRAF1LCKRET | |
| SCHEMBL4845256 | 0.91 | KDR (0.54) | KDRKITRAF1LCKRET | |
| SCHEMBL4850597 | 0.91 | KDR (0.63) | KDRKITRAF1LCKRET | |
| SCHEMBL4850603 | 0.91 | KDR (0.63) | KDRKITRAF1LCKRET | |
| SCHEMBL4846748 | 0.90 | KDR (0.58) | KDRKITRAF1LCKRET | |
| SCHEMBL4846740 | 0.90 | KDR (0.58) | KDRKITRAF1LCKRET | |
| SCHEMBL14019057 | 0.90 | KDR (0.59) | KDRKITRAF1LCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006034110-A1 | (ARYLAMIDOARYL) CYANOGUANIDINE COMPOUNDS AS INHIBITORS OF C-KIT PROTO-ONCOGENE | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-7439256-B2 | (Arylamidoaryl) cyanoguanidine compounds | OSI PHARMACEUTICALS, INC. | 2008-10-21 | — | — | US | disclosed |
| US-20060074082-A1 | (Arylamidoaryl)cyanoguanidine compounds | OSI PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006034110-A1 | (ARYLAMIDOARYL) CYANOGUANIDINE COMPOUNDS AS INHIBITORS OF C-KIT PROTO-ONCOGENE | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074082-A1 | (Arylamidoaryl)cyanoguanidine compounds | NQO2, NRAS, Q6ZSR9 | KDR 1751/4885KIT 1210/4885RAF1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.